ASH 2022 | Journaal Non-Hodgkin Lymfoom (NHL)

In dit journaal bespreekt dr. Elly Lugtenburg haar selectie van het belangrijkste ASH-nieuws op het gebied van non-Hodgkin lymfomen. 

De volgende abstracts komen in dit journaal ter sprake:

Nieuwe eerste- en tweedelijns behandelopties bij mantelcellymfoom

• 1. Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

• 74. Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

Eerste- en tweedelijns behandeling met lenalidomide bij folliculair en diffuus grootcellig B-cellymfoom

• 950. Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

• 323. Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study

• 851.A Propensity Score-Adjusted Comparison of Lenalidomide + R-CHOP Versus R-CHOP for MYC-Rearranged DLBCL Patients

Epcoritamab in combinatie met bestaande therapieën bij folliculair lymfoom en diffuus grootcellig B-cellymfoom

• 609 Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update

• 611 Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

• 443 Subcutaneous Epcoritamab + R-Dhax/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1/2 Results

Bekijk hier het volledige overzicht van onze ASH 2022 journaals en interviews.